A Prospective Study of Expression Profiling-based Assessment of the Efficacy of Neoadjuvant Therapy for Rectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

118 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-01

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective study of expression profiling-based assessment of the efficacy of neoadjuvant therapy for rectal cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rectal Cancer Neoadjuvant Therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rectal cancer patients receiving neoadjuvant therapy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years, male or infertile female
* Patients with rectal adenocarcinoma diagnosed by colonoscopic biopsy
* Neoadjuvant therapy according to guideline recommendations
* Endoscopic biopsy with access to biopsy tissue for subsequent RNA-seq testing
* Patients who do not have a combination of primary malignant tumors elsewhere.
* Patients who understand the purpose of the trial, participate voluntarily and sign an informed consent form.

Exclusion Criteria

* Samples are not collected, stored, or processed in accordance with specified requirements
* Sample does not meet the requirements for subsequent RNA-seq testing
* Cases enrolled with a subsequent diagnosis other than rectal adenocarcinoma.
* The patient refuses or is unable to complete the entire neoadjuvant treatment
* Lack of post-neoadjuvant imaging results and lack of routine postoperative pathology results.
* Other patients who, in the judgment of the investigator, do not meet the enrollment requirements

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jing Sun

Role: CONTACT

Phone: +86-13524284622

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RNA-seq-Neo

Identifier Type: -

Identifier Source: org_study_id